Vesilute

Vesilute is a synthetic dipeptide composed of glutamic acid and aspartic acid (Glu-Asp). Its molecular formula is C9H14N2O7, molecular weight approximately 262 Da. It belongs to the Khavinson class of short peptide bioregulators developed at the St. Petersburg Institute of Bioregulation and Gerontology since the 1970s and is positioned as the synthetic Cytogen counterpart to the bladder Cytomax peptide complex Chitomur.

The Khavinson bioregulator program produced two parallel classes of compounds. Cytomaxes are peptide complexes extracted from organ tissues of young calves (typically under 12 months). They contain multiple short peptides with molecular weights up to several thousand Daltons and are marketed under names like Chitomur (bladder), Ventfort (vessels), Svetinorm (liver), and Cerluten (brain). Cytogens are short synthetic peptides, typically two to four amino acids, designed to reproduce single active sequences identified within the corresponding Cytomax extract. Vesilute is one such Cytogen.

The proposed mechanism for Cytogens is direct DNA interaction. The Khavinson group has published multiple papers describing short-peptide entry into cell nuclei, binding to AT-rich promoter regions, and modulation of tissue-specific gene transcription. The 2020 paper Khavinson et al. in Biomedicines summarizes the binding model. Independent confirmation of this mechanism by groups outside the Khavinson network is sparse.

The Human Evidence

This is where Vesilute sits in unusually weak territory even by Khavinson-class standards. The compound is among the least independently studied bioregulators in the system.

The primary human-evidence base consists of:

• Russian-institution clinical observation studies in elderly patients with bladder dysfunction, chronic cystitis, and benign prostatic hyperplasia. Most are published in Russian-language journals not indexed in PubMed or Embase.
• Internal St. Petersburg Institute reports describing improvements in urodynamic parameters and quality-of-life scales after Vesilute capsule administration.
• Animal model work in rats with infravesical obstruction, examining detrusor muscle behavior and smooth muscle tone.

None of this evidence is an English-language randomized placebo-controlled trial. None has been replicated by independent Western groups. PubMed indexing for Vesilute returns zero clinical trials as of May 2026. The compound's bladder-tissue specificity is asserted on the basis of mechanism analogy to Prostamax (Lys-Glu-Asp-Pro, KEDP), a related tetrapeptide marketed for prostate tissue.

A reader evaluating Vesilute should understand the asymmetry. The Khavinson bioregulator program has produced peer-reviewed publications across decades and developed a coherent theoretical framework for gene-expression-mediated peptide bioregulation. The compound-specific clinical evidence for Vesilute is a small fraction of that broader work and sits inside a single institutional network.

Regulatory and Legal Status

FDA. Vesilute has no FDA approval for any indication. It is not listed on the bulk drug substances list for compounding pharmacies. Importation is permitted only as a research chemical labeled "not for human consumption."

EMA. No European authorization.

Russia. Vesilute is registered as a biologically active dietary supplement, not as a drug. Russian retail product (Vesilut by NPCRIZ / firm-vita.com) is sold in capsule form at standardized peptide doses through the Khavinson distribution network.

WADA. Not on the 2026 Prohibited List.

Outside Russia, the regulatory status is "research chemical." Vendor product is sold through standard research-chemical channels under "not for human consumption" labeling.

The proposed mechanism follows the broader Khavinson bioregulation model. Short peptides enter cells through PEPT1 or PEPT2 peptide transporters, reach the nucleus, and interact with double-stranded DNA in promoter regions of tissue-specific genes. Binding is sequence-selective; the Glu-Asp motif is hypothesized to recognize particular AT-rich sequences in bladder-related gene promoters and modulate transcription.

The downstream effects in bladder tissue, as described in Khavinson group publications, include normalization of detrusor smooth muscle contractility, modulation of microcirculation in the bladder wall, and adjustment of protein synthesis patterns in urothelial cells. The specific genes affected have not been mapped in independent transcriptomic studies.

A second mechanistic claim is calcium signaling modulation in bladder smooth muscle. The Glu-Asp sequence is proposed to attenuate calcium-dependent contractility, producing a relaxation-type effect on hyperactive detrusor muscle.

Human pharmacokinetic data is not published. Oral bioavailability, plasma half-life, tissue distribution, and clearance kinetics for Vesilute in humans have not been characterized in any peer-reviewed pharmacokinetic study. Animal data on dipeptide absorption suggests rapid hydrolysis to free amino acids in the gut and circulation, which creates a theoretical challenge for any model that requires intact dipeptide to reach bladder tissue. The Khavinson group has addressed this by proposing that the relevant pharmacological event occurs locally in the gut and is then signaled through neural and humoral pathways rather than requiring systemic dipeptide delivery. Independent confirmation of either delivery model is absent.

Reported effects come from two sources: Russian-institution clinical observation studies and user reports from research-chemical communities outside Russia.

Russian-institution reports describe:

• Improvement in urinary frequency and urgency scores in elderly patients
• Reduction in nocturia episodes
• Improvement in urodynamic parameters in patients with benign prostatic hyperplasia
• Symptom relief in chronic cystitis cases
• Possible adjunct effects in radiation-induced cystitis

Research-chemical user reports include:

• Reduced urinary frequency
• Subjective improvement in bladder fullness perception
• Effects perceived after multiple weeks of capsule or subcutaneous use

None of these effects has been quantified in a placebo-controlled trial. The user reports are anecdotal and uncontrolled. The Russian institutional reports are not blinded against placebo and are produced by the same group that developed the compound.

No standardized human dosing protocol supported by independent pharmacokinetic data exists for Vesilute.

The Russian retail product (Vesilut capsules) is dosed as 2 capsules once or twice daily before meals for a 30-day course, with re-dosing courses repeated 3 to 6 months later. Each capsule is 0.275 g, with the peptide-active fraction at approximately 20 mg per daily dose. This dosing schedule comes from the manufacturer protocol and is not supported by published clinical pharmacokinetic studies.

Research-chemical Vesilute is sold as lyophilized powder, typically in 20 mg vials. Subcutaneous dosing protocols circulating in research-chemical communities use 1 to 2 mg per day over 10 to 20 day cycles, with multiple cycles per year. These protocols are extrapolated from generic Khavinson-bioregulator dosing recommendations and are not supported by Vesilute-specific human data.

The compound's small size (262 Da) and lack of published pharmacokinetic data mean that route, dose, and frequency recommendations cannot be evaluated against established absorption, distribution, metabolism, or elimination parameters.

The Khavinson bioregulator class has a notably benign published adverse-event profile. The Russian manufacturer documentation for Vesilut lists individual intolerance to components, pregnancy, and lactation as the only contraindications. No serious adverse events have been formally reported.

This is consistent with the dipeptide structure. Glutamic acid and aspartic acid are non-essential amino acids present in dietary protein. Free dipeptide doses at the milligram level fall within normal dietary peptide exposure ranges. Acute toxicity is unlikely on first principles.

The relevant safety question is not acute toxicity but long-term effects on bladder and urogenital tissue gene expression. Long-term human safety data does not exist in any rigorous form. The Khavinson group reports cumulative safety experience from decades of Russian clinical use, but this is not the same as a controlled long-term safety database with pre-specified endpoints, organ system monitoring, and independent adjudication.

A theoretical concern, raised in Western reviews of the bioregulator literature, is that any compound claimed to modulate gene expression in proliferative tissue carries a hypothetical oncogenic risk. The bioregulator literature includes claims of geroprotective effects against age-related cancer incidence rather than promotion, but the underlying gene-expression studies have not been independently replicated to a standard that would resolve this concern definitively.

Drug-drug interaction data is also absent. Vesilute use alongside other bioregulators or pharmaceutical urological agents has not been studied in controlled trials.

Within the Khavinson system, Vesilute is positioned as the initial-phase Cytogen for urinary-tract bioregulation, often followed by Chitomur capsules as the Cytomax for extended support. The Cytogen-then-Cytomax sequence is the Khavinson clinical protocol for most organ systems.

For prostate-focused protocols, Vesilute is sometimes paired with Prostamax (Lys-Glu-Asp-Pro, KEDP), which shares the Glu-Asp core sequence in a longer tetrapeptide. Mechanistically the two compounds are positioned as complementary: Vesilute targets bladder tissue, Prostamax targets prostate tissue, with theoretical overlap at the urogenital interface.

For broader geroprotective stacks, Vesilute is combined with Epitalon (pineal), Cerluten (brain), and Livagen (liver/immune) under the Khavinson group's "complex bioregulator" protocols. Each compound is claimed to target gene expression in its respective tissue. No combined-stack human trial has been published.

For an external comparator, the closest pharmaceutical category to Vesilute's claimed effects is the muscarinic antagonist class (oxybutynin, tolterodine, solifenacin) used for overactive bladder, but the mechanism, evidence tier, and regulatory status of those agents are entirely different. They are FDA-approved drugs with Phase 3 efficacy data. Vesilute is not a substitute for any of them.

For informational and educational purposes only. Not medical advice. Not for human consumption unless prescribed by a licensed physician for an FDA-approved indication. Consult a qualified healthcare provider before using any peptide or pharmaceutical product.